Poster de conférence
Résumé : Lung cancer has been the leading fatal cancer in men and women for last decades. Currently, non‐specific and non‐selective cytotoxic chemotherapy is delivered by infusion via the parenteral route and causes significant systemic toxicities to the patient with only a modest increase in survival time. Another approach consists to deliver chemotherapeutic drugs to the lung by inhalation in order to maximize local drug concentration at the tumor site and to decrease the systemic toxicities. The efficacy of inhaled temozolomide (TMZ) has previously been demonstrated on a mouse melanoma pseudometastatic lung (N. Wauthoz et al., Eur. J. Pharm. Sci. 2011; 39 : 402‐11) . In this study, TMZ dry powder formulations for inhalation were produced without or with a lipid or a lactose coating, which could influence the aerodynamic and the dissolution characteristics of the powders, and therefore their deposition and their bioactivity in the lung.